Clinical Trial Update: Low Dose Atropine for Symptomatic Vitreous Floaters [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating low-dose atropine for symptomatic vitreous floaters. The study status is currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vitreous Floaters

Drugs mentioned

• Low-dose atropine (atropine)

Snippet

Sponsor: Jeanette Du | Conditions: Vitreous Floaters | Phase 2 | Status: UNKNOWN